1 October 2015. KEI Europe, as a member of the Coalition for Affordable T-DM1, submitted a letter to the UK government requesting the government to take several actions to make the breast cancer drug T-DM1 (trastuzumab emtansine) more affordable. The drug made by Roche (trade name Kadcyla) was declared too expensive for the NHS to provide and was only available in England through the Cancer Drug Fund.
Information regarding the problem, the request, and how you can get involved:
Press Release. "Coalition for Affordable T-DM1 Asks the Government to Employ Crown Use Authority to Lower Price of Expensive Cancer Drug."
Frequently Asked Questions. Regarding T-DM1, intellectual property rights, competition law and the Coalition for Affordable T-DM1.
Sign on letter of support. Fill out the form on this page to join our efforts and sign on to a letter of support of the request for affordable T-DM1.
An overview of the crisis in access to T-DM1 in the UK:
Members of the Coalition for Affordable T-DM1
Organizations
Individuals
Dr. Andrew Hill, PhD, University of Liverpool
Chris Redd, Peninsula College of Medicine and Dentistry
Diarmaid McDonald, Access to Medicines Campaigner
Dr. Mohga Kamal-Yanni, MPhil, MBE, Work on access to medicines
